EndoTAG-1

DRUG4 trials

Sponsors

MediGene, Jules Bordet Institute, SynCore Biotechnology Co., Ltd.

Conditions

Breast CancerBreast NeoplasmsLocally Advanced Pancreatic CancerMetastatic Pancreas CancerPancreatic AdenocarcinomaTriple-Negative Breast Cancer

Phase 2

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

CompletedNCT00448305

MediGeneBreast Neoplasms

Start: 2007-01-31End: 2011-03-31Updated: 2012-01-05

Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer

CompletedNCT01537536

Jules Bordet InstituteBreast Cancer

Start: 2011-11-30End: 2012-11-30Target: 18Updated: 2013-06-17

Phase 3

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

SuspendedNCT03002103

SynCore Biotechnology Co., Ltd.Triple-Negative Breast Cancer

Start: 2016-11-23End: 2027-06-30Target: 420Updated: 2023-04-26

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

CompletedNCT03126435

SynCore Biotechnology Co., Ltd.Locally Advanced Pancreatic Cancer, Metastatic Pancreas Cancer, Pancreatic Adenocarcinoma

Start: 2018-10-16End: 2021-10-08Updated: 2023-05-06

Related Papers

EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435).

Journal of Clinical Oncology2020-05-2010 citations

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

PLoS ONE2016-07-2535 citations

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

2014-04-0182 citations